14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 70 days ( 0 % )
Last Price $0.89 0 %
High/ Low $0.89 - $0.89 0%
Chg 7 Days N/A $0.89 $0.89
Chg 30 Days N/A $0.89 $0.89
Chg 12 mos -68.10 % $2.79 $0.89
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos -35.74 % Width: 1,125.46 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos N/A - $1.17 -100.00 % - 32.00 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Buy Apr 16, 2019 - 107 days
Long MA avg 12 mos Sell Jun 20, 2019 - 62 days
Short/Long MA avg 12 mos Sell Jun 20, 2019 - 62 days
Pivot Short Buy Sep 16, 2019 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc., a clinical development-stage biopharmaceutical company, discovers and develops novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The company’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, which is in two Phase II clinical trials for non-small cell lung cancer and pancreatic cancer patients; tarextumab (anti-Notch2/3, OMP-59... OMED Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT